Jove
Visualize
Contact Us

Related Experiment Videos

Pseudoporphyria induced by voriconazole.

Misty T Sharp1, Thomas D Horn

  • 1Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.

Journal of the American Academy of Dermatology
|July 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inciting commensal human papillomavirus immunity to combat cancer.

Trends in cancer·2025
Same author

Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer.

Cell reports·2025
Same author

Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin.

Cancer cell·2024
Same author

Characterization of T-Helper Immune Phenotype in Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Endorses a Delayed-Type Hypersensitivity Reaction.

The American Journal of dermatopathology·2023
Same author

Perspectives on Use of the Cutaneous Direct Immunofluorescence Assay-Reply.

JAMA dermatology·2022
Same author

Assessment of Clinical and Laboratory Use of the Cutaneous Direct Immunofluorescence Assay.

JAMA dermatology·2021
Same journal

Hypoactive Sexual Desire Disorder in Menopausal Women: Dermatologic Implications of Antiandrogen and Testosterone Therapy.

Journal of the American Academy of Dermatology·2026
Same journal

Incise parallel, section perpendicular to the dermatoglyphs for diagnosis of acral melanocytic lesions-A comment on Thakker et al.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Xue et al, "Defining super-responders is not the same as predicting rituximab response in pemphigus".

Journal of the American Academy of Dermatology·2026
Same journal

Comment on Nie et al. (2026) 'Suicidality Reports in Acne Patients Treated with Isotretinoin and Concomitant Antidepressants: A Descriptive Analysis of FDA Adverse Event Reporting System Data'.

Journal of the American Academy of Dermatology·2026
Same journal

Defining super-responders is not the same as predicting rituximab response in pemphigus.

Journal of the American Academy of Dermatology·2026
Same journal

Eosinophilic fasciitis induced by checkpoint inhibitors: a retrospective multicenter case-series, comparison with eosinophilic fasciitis unrelated to checkpoint inhibition and literature review.

Journal of the American Academy of Dermatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Pseudoporphyria is a rare blistering condition. A new case study links the antifungal drug voriconazole to pseudoporphyria, a cause not previously identified.

Area of Science:

  • Dermatology
  • Toxicology

Background:

  • Pseudoporphyria is a blistering disorder clinically and histologically resembling porphyria cutanea tarda.
  • It is characterized by the absence of elevated urine and serum porphyrins.
  • Known triggers include chronic renal failure, UV radiation, and various medications.

Observation:

  • This report details a case of pseudoporphyria.
  • The condition was attributed to the triazole antifungal agent, voriconazole.
  • Voriconazole is a relatively new medication.

Findings:

  • Voriconazole was identified as the causative agent in this case of pseudoporphyria.
  • This represents the first documented instance of voriconazole-induced pseudoporphyria.

Implications:

Related Experiment Videos

  • This finding expands the list of potential drug-induced causes of pseudoporphyria.
  • Clinicians should consider voriconazole when evaluating patients presenting with pseudoporphyria.
  • Further research may be warranted to understand the mechanism of voriconazole-induced pseudoporphyria.